SAN DIEGO, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (NASDAQ: SKYE) (“Skye” or the “Company”), a clinical stage biotechnology company developing next-generation molecules that modulate G-protein-coupled receptors to treat obesity, overweight, and related conditions, today reported financial results for the second quarter ended June 30, 2025, along with key accomplishments and upcoming milestones.
Related Questions
What were the key financial metrics (revenue, net loss, cash burn) for Q2 2025 and how do they compare to prior quarters?
How does the progress of Skye's GPCR-modulating obesity candidates compare to competitors in the same space?
How might the Q2 results influence analyst sentiment and target price revisions for SKYE?
What are the implications of the Q2 results for the upcoming investor conference or earnings call expectations?
What is the current cash runway and does the Q2 cash burn affect future funding needs?
Which clinical trial milestones were achieved in Q2 and what are the upcoming key dates?
Are there any updates on partnership or licensing agreements that could impact future revenue streams?
Did the company meet or exceed its internal guidance for the quarter?
Did the company provide any forward guidance for Q3 or the full year 2025, and how credible is it?
What regulatory or clinical trial risks were highlighted in the business update that could affect future timelines?